Solid Therapeutics

Executive Summary

Solid Therapeutics is an early-stage oncology company based in Copenhagen, Denmark, spun out from the Center for Basic Metabolic Research at the University of Copenhagen in 2017. The company is developing novel small-molecule therapeutics with a dual mode of action that simultaneously targets cancer cells and immune cells, aiming to treat solid tumors. This differentiated approach seeks to address the limited efficacy of current immunotherapies in cold tumors and overcome resistance mechanisms. While the company has disclosed its platform concept, it remains in the preclinical stage with no publicly disclosed lead candidates or pipeline details. The scientific foundation is promising, leveraging insights from metabolic and immune oncology, but the lack of disclosed data and early stage introduce significant clinical and regulatory risks. Solid Therapeutics will need to demonstrate robust preclinical proof-of-concept, secure substantial funding, and navigate the competitive landscape of cancer immunotherapy to progress toward the clinic.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data for lead candidate40% success
• Q3 2026Series A financing round60% success
• TBDInvestigational New Drug (IND) filing20% success